Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

Share Price is delayed by 15 minutes
Get Live Data
3,960.00    2.00 (0.05%)
Bid:
3,926.00
Ask:
3,930.00
Spread: 4.00 (0.102%)
Market Cap: £14.96b
HLMA Live PriceLast checked at - London Stock Exchange

Intraday Halma Share Chart

Acquisition

23 Jan 2013 09:00

RNS Number : 1738W
Halma PLC
23 January 2013
 



Halma plc ('Halma')

 

ACQUISITION OF BAODING LONGER PUMP

 

 

Halma, the leading safety, health and environmental technology group announces the completion on 23 January 2013 of the acquisition of Thinketron Precision Equipment Company Limited ('TPE') based in Hong Kong and its subsidiaries Baoding Longer Precision Pump Co., Ltd ('Longer Pump') based in China and Langer Instruments Corporation ('LIC') based in the USA.

 

Longer Pump manufactures and markets peristaltic, syringe and gear pumps used in laboratory, medical and industrial applications. LIC is Longer Pump's distributor in the USA.

 

The initial cash consideration was RMB 237 million (£23.7 million) for the share capital of TPE. Deferred consideration of RMB 3 million (£0.3 million), which is adjustable RMB for RMB if the net tangible asset value (NTAV) is over/under a targeted amount, is payable upon agreement of the NTAV. The targeted NTAV includes approximately RMB 22.5 million (£2.25 million) of cash.

 

Unaudited accounts for the year ended 31 December 2012 show adjusted operating profit of RMB 23.5 million (£2.35 million). Audited accounts for the year ended 31 December 2011 show adjusted operating profit of RMB 18.2 million (£1.82 million).

 

Existing management of Longer Pump and LIC will remain in place and will continue to operate the business supported by new Board members appointed from within Halma China. The acquisition, which is expected to be immediately earnings enhancing, has been funded from Halma's cash and debt facilities.

 

Longer Pump will join Halma's Health & Analysis sector within the Fluid Technology sub-sector adding complementary high-value fluid handling products which are sold through a large sales network in China. Approximately 80% of Longer Pump's revenue is generated from China.

 

 

Andrew Williams, Halma's Chief Executive, commented:

 

"Longer Pump's alignment with Halma's growth drivers is strong. Sales of their products are driven by increasing demand for healthcare and healthcare research, as well as the urbanisation and industrialisation within China. Their significant local market knowledge and technical resources will help our Fluid Technology sub-sector accelerate growth in this important region.

 

There are also opportunities for Halma to contribute to the growth of Longer Pump, utilising both the network of regional hub offices which Halma has established within China and the worldwide reach of our Fluid Technology businesses."

 

 

 

 

For further information please contact:

 

Halma plc

Andrew Williams, Chief Executive

Kevin Thompson, Finance Director

 

 

 

+44 (0)1494 721111

MHP Communications

Rachel Hirst/Andrew Jaques

+44 (0)20 3128 8100

 

Notes

 

1.

Exchange rate used: RMB 10/£1.

 

2.

Longer Pump has been specialising in the manufacture of peristaltic pumps, syringe pumps, gear pumps and pump accessories for 15 years. It has significant IP and R&D capabilities with sales to a diverse, mainly non-OEM, customer base.

 

Peristaltic pumps provide reliable solutions for demanding fluid handling applications in the laboratory, industrial and OEM markets.

 

Growth prospects in their core geographic market of China for peristaltic pumps are strong. One industry forecast expects market growth of approximately 12% for the next several years, before increasing to over 20% in 2016.

 

3.

Halma buys successful businesses in safety, health and environmental markets and helps them grow further through investment targeted towards increasing innovation, management development and international expansion. In the past 10 years Halma has spent approximately £400m acquiring 30 businesses with deal sizes ranging from £70m down to below £1m. Although businesses have been acquired in all areas of our activity, the majority of recent acquisitions has been in the Health & Analysis Sector.

 

4.

This statement is not intended to constitute a profit forecast for the current financial period or for any future period. In addition, this statement should not be taken to mean that the earnings per share of Halma will necessarily match or exceed the historic reported earnings per share of Halma.

 

5.

A copy of this announcement, together with other information about Halma and its Fluid Technology businesses, may be viewed on our website: www.halma.com.

 

6.

Halma's next Interim Management Statement will be issued on 14 February 2013.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQBJMPTMBATMJJ
Date   Source Headline
9th Sep 20054:41 pmRNSHolding(s) in Company
2nd Sep 20057:00 amRNSAdoption of IFRS
12th Aug 20059:32 amRNSDirector/PDMR Shareholding
11th Aug 20059:15 amRNSAcquisition
10th Aug 20053:23 pmRNSDirector/PDMR Shareholding
9th Aug 20052:30 pmRNSDirector/PDMR Shareholding
5th Aug 200512:44 pmRNSResult of AGM
3rd Aug 20057:00 amRNSAGM Statement
29th Jul 20054:53 pmRNSBlocklisting Interim Review
27th Jul 200511:11 amRNSHolding(s) in Company
22nd Jul 20054:05 pmRNSAnnual Information Update
19th Jul 20051:24 pmRNSAcquisition
12th Jul 20054:16 pmRNSDirector/PDMR Shareholding
12th Jul 20052:55 pmRNSHolding(s) in Company
6th Jul 20054:37 pmRNSDirector/PDMR Shareholding
5th Jul 20055:16 pmRNSAnnual Report and Accounts
1st Jul 20054:45 pmRNSHolding(s) in Company
29th Jun 20059:56 amRNSDirector Shareholding
24th Jun 20054:53 pmRNSDirector Shareholding
21st Jun 20057:00 amRNSFinal Results
6th Jun 20059:51 amRNSNotice of Board Meeting
28th Apr 20057:00 amRNSTrading Statement
1st Mar 20057:00 amRNSDirectorate Change
8th Feb 200510:15 amRNSDirector Shareholding
17th Jan 20059:30 amRNSBlocklisting Interim Review
17th Jan 20059:26 amRNSDirector Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.